Possible to use them for regenerative therapies, repairing damaged organs or tissues in the body, and treating conditions such as type I diabetes or liver disease
A new method for creating stem cells for the human liver and pancreas, which could enable both cell types to be grown in sufficient quantities for clinical use, has been developed by scientists.
Using the technique, researchers have for the first time been able to grow a pure, self-renewing population of stem cells specific to the human foregut, the upper section of the human digestive system.
These so-called “Foregut stem cells” could then be developed further to produce liver or pancreatic cells. The method significantly improves on existing techniques for cultivating this type of stem cell, and raises the possibility that, with further work, they could be grown in large numbers in bioreactors. That would make it possible to use them for regenerative therapies, repairing damaged organs or tissues in the body, and treating conditions such as type I diabetes or liver disease.
“We have developed a cell culture system which allows us to specifically isolate foregut stem cells in the lab,” Dr Nicholas Hannan, from the University of Cambridge Wellcome Trust MRC Stem Cell Institute, Department of Surgery, explained. Hannan led the study, which was carried out in the lab of Dr Ludovic Vallier.
“These cells have huge implications for regenerative medicine, because they are the precursors to the thyroid upper airways, lungs, liver, pancreas, stomach and biliary systems. We now have a system where we may be able to create all these cell types from the same starting population.”
As reported in the journal Stem Cell Reports, the method also means that researchers will be able to analyse the embryonic development of foregut cells in greater depth. “We now have a platform from which we can study the early patterning events that occur during human development to produce the intestines, liver, lungs and pancreas,” Hannan added.
The approach marks a breakthrough because it overcomes some of the problems which currently limit scientists’ abilities to grow cells associated with the liver, pancreas, and other parts of the foregut in sufficiently large numbers for clinical use.
Stem cell growth starts with human pluripotent stem cells (hPSCs). These are non-specialised biological cells with the potential to transform – or “differentiate” – into any of the three primary layers of cells from which all tissues and organs develop. Because these cells also self-renew, creating copies of themselves, they offer the potential to provide an infinite source of clinically usable cells for regenerative medicine.
Go deeper with Bing News on:
- Transplant patient recovers from COVID-19 after receiving donated plasmaon June 29, 2020 at 10:58 am
Running out of time and options, Diaz’s doctors at the University of Chicago Medicine invited him to participate in one of the hospital’s COVID-19 clinical trials where he’d receive convalescent ...
- Avalon GloboCare's CAR-T therapy completes early-stage study in B-cell malignancieson June 29, 2020 at 10:51 am
Avalon GloboCare (AVCO -6.4%) completes Phase I first-in-human clinical study of its lead Chimeric Antigen Receptor (CAR) T-cell therapy candidate, AVA-001.Nine out of ten patients with relaps ...
- Multiple Myeloma Therapy Market is projected to record a significantly high CAGR over the forecast period, i.e., 2020-2028on June 29, 2020 at 10:23 am
Research Nester released a report titled "Multiple Myeloma Therapy Market: Global Demand Analysis & Opportunity ...
- Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001on June 29, 2020 at 6:30 am
CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia - Achieved 90% Complete Remission (CR) ...
- Cytomegalovirus Disease Prevention in High-Risk Liver Transplant Patients: Preemptive Therapy or Prophylaxis?on June 29, 2020 at 5:45 am
Cytomegalovirus (CMV) is a common pathogen post-transplant. CMV-seronegative patients lack personal immunity. If they receive organ transplants from seropositive donors, the risk for infection from ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- COVID-19 Impact and Recovery Analysis- Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavioon June 26, 2020 at 3:00 pm
Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report ...
- Global Stem Cell Market Assessment 2020-2025 - Growing Demand for Regenerative Treatment Optionson June 26, 2020 at 1:29 am
Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering. The global stem cell market is experiencing growth, owing to the increasing number of clinical ...
- These muscle cells are guideposts to help regenerative flatworms grow back their eyeson June 25, 2020 at 11:03 am
If anything happens to the eyes of the tiny, freshwater-dwelling planarian Schmidtea mediterranea, they can grow them back within just a few days. How they do this is a scientific conundrum—one that ...
- Regenerative Medicine Market 2020 Top Manufacturers, Analysis, Industry Size, Future Trends and Industry Growth Research Report 2025on June 25, 2020 at 4:00 am
Final Report will add the analysis of the impact of COVID-19 on this industry” Global “Regenerative Medicine Market” report studies the market in-depth and provides an all-encompassing analysis of the ...
- The Alliance for Regenerative Medicine Announces Its 2020 Cell & Gene Meeting on the Mesa Goes Virtualon June 24, 2020 at 10:19 am
Washington, DC, June 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), an international multi-stakeholder advocacy organization representing the ...